, Tooran Nayeri Chegeni1,2,3
, Mehdi Sharif1,2,4
, Mahbobeh Montazeri1,2
, Seyed Abdollah Hosseini1,2
, Afsaneh Amouei1,2
, Zahra Hosseininejad1,2,3
, Davood Anvari1,2,3
, Reza Saberi1,2,3
, Shaban Gohardehi1,2
, Ahmad Daryani1,2
1Toxoplasmosis Research Center, Mazandaran University of Medical Sciences, Sari, Iran
2Department of Medical Parasitology, School of Medicine, Mazandaran University of Medical Sciences, Sari, Iran
3Student Research Committee, Mazandaran University of Medical Sciences, Sari, Iran
4Department of Parasitology, School of Medicine, Sari Branch, Islamic Azad University, Sari, Iran
©2019, Korean Society of Epidemiology
This is an open-access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
| Study | City | Neonates (n) | IgG (n) | IgM (n) | PCR (n) | Method | Design |
|---|---|---|---|---|---|---|---|
| Alameh et al., 2002 [24] | Isfahan | 18 | 7 | 0 | - | IFA | Cross-sectional |
| Gharavi, 2003 [22] | Tehran | 18 | 18 | 8 | - | IFA, ISAGA | Cross-sectional |
| Assmar et al., 2004 [25] | Tehran | 11 | 11 | 4 | 4 | PCR | Cross-sectional |
| Mehbod et al., 2005 [26] | Tehran | 210 | 79 | 8 | - | ELISA, IFA | Cross-sectional |
| Shaddel et al., 2007 [27] | Tehran | 104 | ELISA: 38, IFA: 60 | ELISA: 6, IFA: 5, total: 7 | 6 | ELISA, IFA, PCR | Cross-sectional |
| Golalipour et al., 2009 [28] | Gorgan | 64 | 23 | 2 | - | ELISA | Cross-sectional |
| Noorbakhsh et al., 2012 [29] | Tehran | 50 | 9 | 5 | - | ELISA | Case-control |
| Noorbakhsh et al., 2013 [30] | Tehran | 270 | 119 | 4 | 0 | ELISA, PCR | Cohort |
| Zavari et al., 2015 [31] | Rafsanjan | 254 | 83 | 1 | - | ELISA | Cross-sectional |
| Rasti et al., 2015 [32] | Kashan | 9 | 9 | 0 | 3 | ELISA, PCR | Cohort |
| Shieh et al., 2017 [33] | Arak | 261 | 37 | 3 | 1 | ELISA, PCR | Cross-sectional |
| Study | Selection (3 points) | Comparability (2 points) | Outcome (3 points) | Total score |
|---|---|---|---|---|
| Alameh et al., 2002 [24] | 3 | 1 | 2 | 6 |
| Gharavi, 2003 [22] | 3 | 1 | 1 | 5 |
| Assmar et al., 2004 [25] | 2 | 1 | 1 | 4 |
| Mehbod et al., 2005 [26] | 3 | 1 | 1 | 5 |
| Shaddel et al., 2007 [27] | 2 | 0 | 1 | 3 |
| Golalipour et al., 2009 [28] | 2 | 1 | 1 | 4 |
| Noorbakhsh et al., 2012 [29] | 3 | 2 | 1 | 6 |
| Noorbakhsh et al., 2013 [30] | 3 | 2 | 2 | 7 |
| Zavari et al., 2015 [31] | 3 | 2 | 2 | 7 |
| Rasti et al., 2015 [32] | 2 | 2 | 2 | 6 |
| Shieh et al., 2017 [33] | 3 | 2 | 2 | 7 |
IgG, immunoglobulin G; IgM, immunoglobulin M; PCR, polymerase chain reaction; IFA, immunofluorescence assay; ISAGA, immunosorbent agglutination assay; ELISA, enzyme-linked immunosorbent assay.
Good: 7-9; fair: 4-6; poor: ≤3 for case-control studies and good: 6-7; fair: 3-5; poor: 1-2 for cross-sectional studies.